Các phác đồ liều lượng khác nhau của vắc xin protein gai SARS-CoV-2 tái tổ hợp (NVX-CoV2373) ở người lớn trẻ và già: Thử nghiệm đối chứng ngẫu nhiên giai đoạn 2
Tóm tắt
Từ khóa
Tài liệu tham khảo
World Health Organization, 2021, Coronavirus disease (COVID-19) dashboard
KL Bengtsson, 2016, Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice, Vaccine, 34, 1927, 10.1016/j.vaccine.2016.02.033
C Keech, 2020, Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine, N Engl J Med, 383, 2320, 10.1056/NEJMoa2026920
L Du, 2009, The spike protein of SARS-CoV–a target for vaccine and therapeutic development, Nat Rev Microbiol, 7, 226, 10.1038/nrmicro2090
W Tai, 2020, Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine, Cell Mol Immunol, 17, 613, 10.1038/s41423-020-0400-4
LR Baden, 2021, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med, 384, 403, 10.1056/NEJMoa2035389
FP Polack, 2020, C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577
K Karthik, 2020, Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19, Hum Vaccin Immunother, 16, 3055, 10.1080/21645515.2020.1796425
Food and Drug Administration. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. September 2007. [cited 2021 Mar 6]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical.
Division of AIDS (DAIDS), National Institutes of Health. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 2.1. July 2017. [cited 2021 Mar 6]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.
D2.3 Priority List of Adverse Events of Special Interest: COVID-19. V2.0. 2020 May 25. [cited 2021 Mar 6]. Available from: https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf.
V Shinde, 2021, Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant, N Engl J Med, 384, 1899, 10.1056/NEJMoa2103055
L Fries, 2017, Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults, Immun Ageing, 14, 8, 10.1186/s12979-017-0090-7
SA Madhi, 2020, Respiratory syncytial virus vaccination during pregnancy and effects in infants, N Engl J Med, 383, 426, 10.1056/NEJMoa1908380
FM Munoz, 2019, Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants, J Infect Dis, 220, 1802, 10.1093/infdis/jiz390
GM Glenn, 2016, A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age, J Infect Dis, 213, 411, 10.1093/infdis/jiv406
V Shinde, 2020, Induction of cross-reactive hemagglutination inhibiting antibody and polyfunctional CD4+ T-cell responses by a recombinant Matrix-M-adjuvanted hemagglutinin nanoparticle influenza vaccine, ciaa1673
V Shinde, 2020, Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a randomized controlled trial
V Shinde, 2018, Improved titers against influenza drift variants with a nanoparticle vaccine, N Engl J Med, 378, 2346, 10.1056/NEJMc1803554
L Fries, 2020, Randomized, blinded, dose-ranging trial of an Ebola virus glycoprotein nanoparticle vaccine with matrix-m adjuvant in healthy adults, J Infect Dis, 222, 572, 10.1093/infdis/jiz518
PT Heath, 2021, Safety and efficacy of NVX-CoV2373 Covid-19 vaccine [published online ahead of print, 2021 Jun 30], N Engl J Med, NEJMoa2107659
J Sadoff, 2021, Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19, N Engl J Med, 384, 2187, 10.1056/NEJMoa2101544
M Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [published correction appears in Lancet 2021;397(10269):98]., Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1
DY Logunov, 2021, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia [published correction appears in Lancet 2021;397(10275):670]., Lancet, 397, 671, 10.1016/S0140-6736(21)00234-8
N Dagan, 2021, BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting, N Engl J Med, 384, 1412, 10.1056/NEJMoa2101765
E Vasileiou, 2021, Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study, Lancet, 397, 1646, 10.1016/S0140-6736(21)00677-2
KRW Emary, 2021, Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial, Lancet, 397, 1351, 10.1016/S0140-6736(21)00628-0